Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

However, a "big quantum leap" was the marked improvement in engraftment and the reduction of graft-versus-host disease (GVHD) ...

Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Graft Versus Host Disease (GVHD).

Memorial Sloan Kettering Cancer Center physicians describe challenges in diagnosis, patient care, and the potential expansion of telehealth in this continuation of November's coverfeature.

TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

It's a lost opportunity to promote a healthy gut microbiome, recover from treatment-related microbiota injury, and protect against GVHD," said first author Jenny Paredes, PhD, a staff scientist at ...

Morgans analyst Iain Wilkie said 2024 was "pretty patchy" for the ASX healthcare sector, which underperformed broader markets ...

Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares.